Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
about
Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials.Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial.Effects of verapamil slow release plus trandolapril combination therapy on essential hypertensionHypertension in patients with diabetes. Strategies for drug therapy to reduce complications.Calcium channel blockers - the effect on renal changes in clinical and experimental diabetes: an overview.Progressive renal insufficiency. Office strategies to prevent or slow progression of kidney disease.Managing hypertension in patients with renal disease and diabetes.Evaluation of antihypertensive therapy in diabetic hypertensive patients: impact of ischemic heart disease.Renal protective potential of antihypertensive drugs.Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes.Pathophysiologic therapeutic targets in hypertension: a cardiological point of view.The fixed combination of verapamil SR/trandolapril.Blood pressure in diabetic nephropathy--current controversies.Slowing the progression of renal disease in diabetic patients.Evidence-based treatment of hypertension in patients with type 2 diabetes.Diabetic nephropathy - complications and treatment.Prescribing patterns and therapeutic implications for diabetic hypertension in Bahrain.Pharmacotherapy of hypertension in patients with diabetes mellitus.Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension.Management of the patient with chronic renal failure in the evidence based era.Evidence-based treatment of hypertension in patients with diabetes mellitus.Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors.Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines.Diabetic renal disease: from recent studies to improved clinical practice.Evidence-based guide to slowing the progression of early renal insufficiency.Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor.Blood pressure control and nephroprotection in diabetes.Calcium channel blockers in the prevention of end stage renal disease: a review.The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.Diabetic nephropathy: the proteinuria hypothesis.Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.Management strategies for patients with hypertension and diabetes: why combination therapy is critical.Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination.Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney DiseaseTrandolapril/verapamil combination in hypertensive diabetic patients.Chronic kidney disease (CKD) in the elderly -- a geriatrician's perspective.Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker.Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?Cardiovascular disease in transplant recipients: current and future treatment strategies.
P2860
Q33599683-EE88CF74-1875-4296-A206-43DF96EECAB5Q33738945-B872C022-F3D3-41F7-8562-880587E62433Q33738993-0538B80C-B2ED-42E9-9C51-1650BDD4BCDDQ33897700-4EC61D94-F82D-42C5-BCE1-78BA7ABB2C20Q33917790-7FC388A7-7008-4DCB-A04D-C08888C78EFEQ33983309-BB893F93-74F4-4A4C-BD14-90EE633DF99FQ34034877-099071CE-3B1F-4BAD-A8BC-935742431616Q34072091-6677A2BF-9F23-4407-BD7B-329FA719C8FEQ34075168-B58DCD72-8113-4447-875A-40226E86FA8AQ34075171-7FA6EA37-95E2-4A9A-8B77-B737A50D28FAQ34142036-722B5F7D-3A58-4F4C-A18F-F86AA804B9A5Q34182205-81A97C84-E280-4425-9F50-8D6E355028CBQ34212822-605B1D48-4A80-4667-8F72-3B14D1206CA2Q34219071-13B40506-0C62-46CB-9DB6-363AF9841081Q34267980-B747A4ED-76EE-4F5D-8A53-E99B61DD7DB1Q34387952-17C0429A-A60B-403C-8E4D-47AC22AAB581Q34449421-58A49775-29F4-451A-B647-B47A66032D3FQ34515483-D718885E-4BB0-40A0-A7C0-BFEC79E9BC54Q34849534-F1612DA4-842C-46AD-A73B-AD057ACDFC4DQ35047912-F3BF0437-F540-49C8-8B49-7C168637020CQ35050989-4B32DE31-2498-44D0-8E00-9B0AD124F03AQ35210587-146013A7-FA24-404A-911C-F1A70E6BA0F8Q35591053-BC0EAD3C-F419-442E-BFA5-BFB1642D10E5Q35620727-DEAD4267-D705-41AA-9D82-C306A3C05BA5Q35641499-49EC50FC-1CC4-49BB-B164-62165EE422DDQ35686501-5D049BD9-51E9-47F7-B12C-6DEE628873FAQ35722933-B697BB86-9459-4EDB-A9C9-6ED093E740DAQ35738806-42C48FC0-C951-4BF7-9B4E-C5244BCABC61Q35880931-A4B93F05-3401-4A54-B369-4061A599A717Q36061335-9654BECC-942E-462F-92D5-12C1F1E43074Q36289427-EFDFA229-7838-43A6-9D8A-F23504C5E73BQ36329456-2E54FC0B-6AF6-4121-A180-3568CF0C8793Q36392677-A0A45AF9-B2F6-4C92-B074-CE64E849DA2CQ36536275-7ED24BFF-48F6-4CC3-B6E1-CFB3E127DCABQ36720082-1C98BED3-D9F6-4600-B1BF-A25C610C4A23Q36855021-B4620A0A-3D7C-4724-8BDB-AA4E4CA8572BQ36911521-FDB94E99-B1EF-49B1-9D56-5FB0D32AFED4Q36961390-0AA7A4CF-27F2-4029-810D-2E71FDE4856EQ37078827-FE66C8A0-6520-47A0-94D5-5CF799560DF8Q37097700-85966B58-4292-4AE7-8699-775F181D13F8
P2860
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Effects of an ACE inhibitor/ca ...... nuria in diabetic nephropathy.
@ast
Effects of an ACE inhibitor/ca ...... nuria in diabetic nephropathy.
@en
Effects of an ACE inhibitor/ca ...... nuria in diabetic nephropathy.
@nl
type
label
Effects of an ACE inhibitor/ca ...... nuria in diabetic nephropathy.
@ast
Effects of an ACE inhibitor/ca ...... nuria in diabetic nephropathy.
@en
Effects of an ACE inhibitor/ca ...... nuria in diabetic nephropathy.
@nl
prefLabel
Effects of an ACE inhibitor/ca ...... nuria in diabetic nephropathy.
@ast
Effects of an ACE inhibitor/ca ...... nuria in diabetic nephropathy.
@en
Effects of an ACE inhibitor/ca ...... nuria in diabetic nephropathy.
@nl
P2093
P1433
P1476
Effects of an ACE inhibitor/ca ...... nuria in diabetic nephropathy.
@en
P2093
P304
P356
10.1046/J.1523-1755.1998.00083.X
P407
P577
1998-10-01T00:00:00Z
P5875
P6179
1023884632